Table 1.
Demographic and clinical information for each center participating in the INNI initiative (the statistically significant differences are reported in bold)
| Center A | Center B | Center C | Center D | Total | |
|---|---|---|---|---|---|
| Patients/controls | 260/99 | 141/94 | 72/37 | 16/16 | 489/246 |
| Age, mean ± sd | |||||
| Patients | 40.9 ± 12.3 | 37.1 ± 10.3 | 40.3 ± 11.0 | 42.7 ± 7.18 | 39.8 ± 11.6 |
| Controls | 38.1 ± 13.5 | 38.2 ± 11.6 | 37.2 ± 12.8 | 42.6 ± 6.97 | 38.3 ± 12.4 |
| p (t value) | 0.08 (1.78) | 0.45 (− 0.76) | 0.21 (1.27) | 0.98 (0.02) | 0.12 (1.55) |
| Sex | |||||
| Patients | 156 F/104 M | 94 F/47 M | 54 F/18 M | 12 F/4 M | 316 F/173 M |
| Controls | 51 F/48 M | 54 F/40 M | 23 F/14 M | 12 F/4 M | 140F/106 M |
| p ( value) | 0.15 (2.11) | 0.15 (2.06) | 0.16 (1.94) | 1.00 (0.00) | 0.04 (4.13) |
| MS phenotype (RR/SP/PP/CIS/B) | 166/53/18/0/23 | 122/4/1/14/0 | 65/3/1/3/0 | 15/0/0/0/1 | 368/60/20/17/24 |
| Disease duration, mean ± sd | 12.7 ± 8.54 | 11.1 ± 8.98 | 9.57 ± 6.52 | 8.56 ± 9.14 | 11.9 ± 8.52 |
| EDSS, median (IQR) | 2 (3) | 2 (1.5) | 1.5 (1.5) | 1.5 (0.5) | 2 (2.5) |
| SDMT, mean ± sd | 42.5 ± 16.0 | 40.3 ± 14.7 | 45.2 ± 11.4 | 45.8 ± 13.4 | 42.4 ± 15.0 |